期刊文献+

流感病毒快速诊断试剂中HA抗原热稳定性的研究 被引量:4

Study on the Heat Stability of HA Antigen in Influenza Virus Rapid Diagnosis Kit
下载PDF
导出
摘要 [目的]筛选流感病毒HA抗原保护剂。[方法]将H3N2和H1N1亚型流感病毒分别加入A~F组中,在37℃下进行加速试验,并通过血凝试验测定HA滴度。[结果]在28 d A组(添加PBS缓冲液)中H3N2和H1N1亚型流感病毒的HA抗原血凝滴度分别为20和32。F组(添加BSA、岩藻糖、Proclin 300、Triton 100)HA抗原的热稳定性最好,在28 d H3N2和H1N1亚型流感病毒HA抗原血凝滴度分别为48和96。[结论]F组成分对流感病毒HA抗原的保护作用最好,可作为保护剂候选配方。 [Objective] The research aimed to screen out the protective agent of influenza virus.[Method] H3N2 and H1N1 subtypes of influenza virus were added to A-F groups to make the accelerated test at 37 ℃.And HA titer was test by hemagglutination test.[Result] HA antigen hemagglutination titer of H3N2 and H1N1 subtype of influenza virus in A group(adding PBS buffer)were 20 and 32 respectively after 28 days.The heat stability of HA antigen in F group(adding BSA,fucose,Proclin 300,Triton 100)were the best and HA hemagglutination titer of H3N2 and H1N1 subtype of influenza virus were 48 and 96 respectively after 28 days.[Conclusion] The components in F group had the best protective effects on HA antigen of influenza virus and could be used as the candidate agent of protective agent.
出处 《安徽农业科学》 CAS 2012年第16期8935-8936,共2页 Journal of Anhui Agricultural Sciences
基金 国家863项目(2006AA02Z409) 云南省自然科学基金项目(2004C07-0M) 云南省国内科技合作项目(2006YX29)
关键词 流感病毒 HA抗原 热稳定性 保护剂 Influenza virus HA antigen Heat stability Protective agent
  • 相关文献

参考文献8

  • 1ITO T,ALLEN M,CARSON W F IV,et al. The critical role of Notch ligand delta-like 1 in the pathogenesis of influenza A virus ( H1 N1 ) infection [ J ]. Plos Pathogen ,2011 ,7 ( 11 ) : 1002341.
  • 2SALOMON R,WEBSTER R G. The influenza virus enigma[J]. Cell ,2009, 136(3) :402 -410.
  • 3张钫,张舒.甲型流感病毒的变异及其跨物种传播[J].国外医药(抗生素分册),2010,31(2):63-67. 被引量:5
  • 4World Health Organization. Expanded programme on immunization:The effects of freezing on the appearance,potency and toxicity of a adsorbed un adsorbed DTP vaccine [ J ]. Weekly Epidemiol Record, 1980,55:252 - 256.
  • 5姚亚夫,张卓光,王洪彬,周蓉,李玉华,史东惠,彭维,张大全,何建琴,张艳,王寿贵.提高麻疹乙脑二联活疫苗热稳定性的研究[J].中国生物制品学杂志,1998,11(1):25-27. 被引量:7
  • 6王寿贵,杨洪举,邓远运,王方保,郑庆纹,俞永新.乙型脑炎14-2株冻干活疫苗的生产研究[J].病毒学报,1990,6(1):38-43. 被引量:13
  • 7MELNICK J L. Thermostability of poliovirus,measles ,and hepatitis B Vac- cines[J]. Vaccine Research ,1995,4( 1 ) :129.
  • 8SOOD D K,AGGARWAN R K,SHARMA S B,et al. Study on the stability of 17D204 yellow fever vaccine before and after stabilization[J]. Vaccine, 1993,11 (11) :1124 -1131.

二级参考文献43

  • 1周晓明,赵慧芳,陆嘉良,潘浩,徐眉,赵根明,姜庆五,汪华,俞顺章.甲型流感病毒基因变异与生存选择压力相关性分析[J].中华传染病杂志,2005,23(4):221-224. 被引量:9
  • 2王寿贵,杨洪举,邓远运,王方保,郑庆纹,俞永新.乙型脑炎14-2株冻干活疫苗的生产研究[J].病毒学报,1990,6(1):38-43. 被引量:13
  • 3Webster RG, Bean WJ, Gorman OT,et al. Evolution and ecology of influenza A viruses [J]. Microbiol Rev,1992, 56 (1):152.
  • 4Ledford. Old seasonal flu antibodies target swine flu virus [J]. Nature, online 21 May 2009.
  • 5Basak I, Pemra D, Ivet B. Functional motions of influenza virus hemagglutinin: A structure-based analytical approach [J]. Biophys J, 2002, 82:569.
  • 6Ito T, Gorman OT, Kawaoka Y, et al. Evolutionary analysis of the influenza A virus M gene with comparison of MI and M2 protein [J]. J Virol, 1991, 65(10): 5491.
  • 7Neumann G, Hughes MT, Kawaoka Y. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRMI [J]. EMBO J,2000, 19(24): 6751.
  • 8Shimizu K. Mechanisms of antigenic variation in influ enza virus [J]. Nippon Rinsho, 1997, 55(10): 2610.
  • 9Chen JZ, Deng YM. Influenza virus antigenic variation,host antibody production and new approach to control epidemic [J]. Virol J, 2009, 6:(30).
  • 10Hinshaw VS, Webster RG, Turner B. The perpetuation of orthomyxoviruses and para -myxoviruses in Canadian waterfowl [J]. Can J Microbiol, 1980, 26(5): 622.

共引文献21

同被引文献41

  • 1顾鸣,邵盖斌,顾勤,吴维峥.低浓度牛血清培养Vero细胞的研究[J].中国生物制品学杂志,1995,8(1):28-30. 被引量:1
  • 2王永民,陈昭烈.动物细胞无血清培养基的研究与设计方法[J].中国生物工程杂志,2007,27(1):110-114. 被引量:15
  • 3WHO.Human infection with influenza A(H7N9)virus in China[J].N Engl J Med,2013,368:1888-1897.
  • 4Mendelman PM,Cordova J,Cho I.Safety,efficacy and effectiveness of the influenza virus vaccine,trivalent,types A and B,live,cold-adapted(CAIV-T)in healthy children and healthy adults[J].Vaccine,2001,19(17-19):2221-2226.
  • 5Nerome K,Kumihashi H,Nerome R,et al.Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model[J].Dev Biol Stand,1999,98(1):53-63,73-74.
  • 6Kistner O,Barrett PN,Mundt W,et al.Development of a mammalian cell(Vero)derived candidate influenza virus vaccine[J].Vaccine,1998,16(9-10):960-968.
  • 7Tree JA,Richardson C,Fooks AR,et al.Comparison of largescale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains[J].Vaccine,2001,19(25-26):3444-3450.
  • 8Barrett PN,Mundt W,Kistner O,et al.Vero cell platform in vaccine production:moving towards cell culture-based viral vaccines[J].Expert Rev Vaccines,2009,8(5):607-618.
  • 9Job ER,Bottazzi B,Gilbertson B,et al.Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses[J].PLoS One,2013,8(3):e59623.
  • 10Peschel B,Frentzel S,Laske T,et al.Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line[J].Vaccine,2013,31(48):5693-5699.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部